Table 2:
Clinical characteristics of all participants and adherent participants at baseline
| Characteristics | All Participants n=204 | Patients adherent* to protocol n=142 | |
|---|---|---|---|
| Average # sessions attended | 8.31±4.11 | 10.70±1.06 | |
| Age (years) | 52 (41–60) | 54 (39–62) | |
| Sex | Male | 62 (31%) | 45 (32%) |
| Female | 141 (69%) | 97 (68%) | |
| Height (cm) | 167.01 (161.29–175.26) | 168.28 (162.40–177.8) | |
| Weight (kg) | 108.82 (96.38–125.95) | 108.82 (97.07–124.87) | |
| BMI (kg/m²) | 38.3 (35.3–42.1) | 38.2 (35.4–42.0) | |
| Race | White | 167 (82%) | 122 (86%) |
| Black | 9 (4%) | 6 (4%) | |
| Asian | 3(2%) | 2 (1%) | |
| Unknown | 25 (12%) | 12 (9%) | |
| Glucose (mg/dL) | 95 (86–109) (n=198) | 95 (85.8–109.3) (n=138) | |
| ALT (U/L) | 23 (17–36) (n=199) | 22 (18–27) (n=138) | |
| AST (U/L) | 23 (18–28) (n=198) | 23 (18–28) (n=138) | |
| Cholesterol (mg/dL) | 191.41±36.68 (n-194) | 193.55±34.16 (n-135) | |
| Triglycerides (mg/dL) | 116.5(81.8–147.3) (n=194) | 115(84–142) (n=135) | |
| HDL (mg/dL) | 49 (39.8–59.0) (n=194) | 49 (39 −59) (n=135) | |
| LDL (mg/dL) | 114.58 ±32.17 (n=186) | 115.91 ±30.95 (n=130) | |
| HbA1c (%) | 5.6 (5.4–6) (n=192) | 5.6 (5.4–6.1) (n=133) | |
| On | |||
| Anti-Obesity Medication | |||
| None | 171 (84%) | 119 (83%) | |
| Metformin | 18 (9%) | 11 (8%) | |
| Bupropion | 7 (3%) | 5 (4%) | |
| Qysmia | 0 | 0 | |
| Phentermine | 3 (1.5%) | 1 (0.1%) | |
| Topiramate | 3 (1.5%) | 2 (0.1%) | |
| Bupropion+Naltrexone | 1 (0.1%) | 1 (0.1%) | |
| Liraglutide | 1(0.1%) | 1(0.1%) | |
| Lorcaserin | 0 | 0 | |
| Zonisamide | 0 | 0 | |
| Exenitide | 0 | 0 | |
| Orlistat | 0 | 0 | |
| Pramlintide | 0 | 0 | |
*
Adherent is defined as attending 9 out of 12 classes.
Data presented as means±SD or median (interquartile range).
Abbreviations: ALT- alanine transaminase, AST- aspartate transaminase, HDL-high density lipoprotein, LDL- low density lipoprotein